Page 63 - Clinical Development News Today

Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The

An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).

Scientific advances and consumer appetite have converged to make the gut-brain axis one of the most exciting areas of research today, according to a leading scientist at ADM.

Scientific advances and consumer appetite have converged to make the gut-brain axis one of the most exciting areas of research today, according to a leading scientist at ADM.

/PRNewswire/ -- The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.coms offering. This report offers...

Greenphire has announced a technology partnership that integrates two of the most popular software solutions in the industry.

A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.

OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc. to discuss a number of issues those working in precision medicine still face.

CluePoints, a company providing risk-based study execution (RBx) and risk-based quality management (RBQM) software for clinical trials has won the best Contract Research Organization (CRO) in the specialist providers category at Citeline’s 2023 SCRIP Awards.

Astellas Pharma Inc. and Pfizer Inc. today announced that the companies received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application for small-molecule drug Xtandi (enzalutamide).